Press "Enter" to skip to content

U.S. FDA approves Stemline Therapeutics’ rare blood disease treatment

The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc’s Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/bTfMKEmzAF4/u-s-fda-approves-stemline-therapeutics-rare-blood-disease-treatment-idINKCN1OK1SQ

Also Read:   Oncquest Lab acquires Quest Diagnostics Indian facilities from Strand